

Amendments to the Claims:

Claims 1-17 (canceled)

Claim 18 (previously presented) A nasal pharmaceutical composition which comprises
(a) at least one active substance suitable for nasal administration, which active substance is selected from the group consisting of xylometazoline, naphazoline, fenoxazoline, oxymetazoline, tetrahydrozoline, tramazoline, phenylephrine, ephedrine, epinephrine, and nasally acceptable salts of any of these compounds,
(b) a mucopolysaccharide which is selected from the group consisting of chondroitin, hyaluronic acid, dermatan, keratan, heparin, acemannan, and nasally acceptable salts of any of said compounds, and
(c) propylene glycol.

Claim 19 (previously presented) A composition according to claim 18, wherein the active substance (a) is xylometazoline or a nasally acceptable salt thereof.

Claim 20 (previously presented) A composition according to claim 18-35, wherein the mucopolysaccharide (b) is chondroitin sulfate.

Claim 21 (previously presented) A composition according to claim 18, wherein propylene glycol (c) is present in an amount of from 0.5 up to 10 % (w/w) of the total composition.

Claim 22 (previously presented) A composition according to claim 18, wherein propylene glycol (c) is present in an amount of from 1.5 up to 5 % (w/w) of the total composition.

Claim 23 (previously presented) A composition according to claim 18, wherein the composition further comprises water as vehicle.

Claim 24 (previously presented) A composition according to claim 18, wherein the composition further comprises a nasally acceptable film-forming agent.

Claim 25 (previously presented) A composition according to claim 18, wherein the composition further comprises an essential oil of a plant.

Claim 26 (previously presented) A composition according to claim 18, wherein the composition further comprises a nasally acceptable preservative.

Claim 27 (previously presented) A composition according to claim 18, wherein the composition is devoid of a nasally acceptable preservative.

Claim 28 (previously presented) A nasal pharmaceutical composition which consists essentially of

- (a) at least one active substance suitable for nasal administration,
- (b) a mucopolysaccharide,
- (c) propylene glycol, and
- (d) water,

with the proviso that said composition is devoid of fexofenadine and pharmaceutically acceptable salts thereof.

Claim 29 (previously presented) A nasal pharmaceutical composition which consists essentially of

- (a) at least one active substance suitable for nasal administration,
- (b) a mucopolysaccharide,
- (c) propylene glycol,
- (d) a nasally acceptable preservative, and
- (e) water,

with the proviso that said composition is devoid of fexofenadine and pharmaceutically acceptable salts thereof.

Claim 30 (previously presented) A composition according to claim 28, wherein the active substance (a) is selected from the group consisting of xylometazoline, naphazoline, fenoxazoline, oxymetazoline, tetrahydrozoline, tramazoline, phenylephrine, ephedrine, epinephrine, and nasally acceptable salts of any of these compounds.

Claim 31 (previously presented) A composition according to claim 28, wherein the active substance (a) is xylometazoline or a nasally acceptable salt thereof.

Claim 32 (previously presented) A nasal pharmaceutical composition according to claim 28, wherein the mucopolysaccharide (b) is selected from the group consisting of chondroitin, hyaluronic acid, dermatan, keratan, heparin, acemannan, and nasally acceptable salts of any of said compounds.

Claim 33 (previously presented) A composition according to claim 32, wherein the mucopolysaccharide (b) is chondroitin sulfate.

Claim 34 (previously presented) A composition according to claim 18, wherein the composition is in the form of drops, a solution, a spray or a metered-dose spray.

Claim 35 (new). A composition according to claim 18, wherein the mucopolysaccharide (b) is chondroitin or a nasally acceptable salt thereof.

Claim 36 (new) A composition according to claim 18, wherein the mucopolysaccharide (b) is hyaluronic acid or a nasally acceptable salt thereof.

Claim 37 (new) A composition according to claim 36, wherein the mucopolysaccharide (b) is sodium hyaluronate.

Claim 38 (new) A composition according to claim 18, wherein the active substance (a) is oxymetazoline or a nasally acceptable salt thereof.

Claim 39 (new) A nasal pharmaceutical composition which comprises
(a) xylometazoline, oxymetazoline, or a nasally acceptable salt thereof,
(b) chondroitin, hyaluronic acid, or a nasally acceptable salt thereof, and
(c) propylene glycol.

Claim 40 (new) A nasal composition according to claim 39 which comprises
(a) xylometazoline or a nasally acceptable salt thereof,
(b) chondroitin or a nasally acceptable salt thereof, and
(c) propylene glycol.

Claim 41 (new) A composition according to claim 39, wherein propylene glycol is present in an amount of from 0.5 up to 10 % (w/w) of the total composition.

Claim 42 (new) A composition according to claim 39 wherein the chondroitin or a nasally acceptable salt thereof, is present in an amount of from 0.25 up to 2%.

Claim 43 (new) A composition according to claim 39 wherein the hyaluronic acid or nasally acceptable salt thereof is present in an amount of from 0.02 up to 1%.

Claim 44 (new) A composition according to claim 40 wherein the chondroitin or a nasally acceptable salt thereof, is present in an amount of from 0.25 up to 2%.

Claim 45 (new) A composition according to claim 44, wherein propylene glycol is present in an amount of from 0.5 up to 10 % (w/w) of the total composition.

Claim 46 (new) A composition according to claim 39 which is preservative-free.

Claim 47 (new) A composition according to claim 40 which is preservative-free.